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Incremental Reduction in Risk of Death Associated With Use of
Guideline-Recommended Therapies in Patients With Heart Failure: A
Nested Case-Control Analysis of IMPROVE HF
Gregg C. Fonarow, MD; Nancy M. Albert, MD; Anne B. Curtis, MD; Mihai Gheorghiade, MD; Yang Liu, MS; Mandeep R. Mehra, MBBS;
Christopher M. O’Connor, MD; Dwight Reynolds, MD; Mary N. Walsh, MD; Clyde W. Yancy, MD
Background—Several therapies are guideline-recommended to reduce mortality in patients with heart failure (HF) and reduced left
ventricular ejection fraction, but the incremental clinical effectiveness of these therapies has not been well studied. We aimed to
evaluate the individual and incremental beneﬁts of guideline-recommended HF therapies associated with 24-month survival.
Methods and Results—We performed a nested case-control study of HF patients enrolled in IMPROVE HF. Cases were patients
who died within 24 months and controls were patients who survived to 24 months, propensity-matched 1:2 for multiple prognostic
variables. Logistic regression was performed, and the attributable mortality risk from incomplete application of each evidence-
based therapy among eligible patients was calculated. A total of 1376 cases and 2752 matched controls were identiﬁed. β-
Blocker and cardiac resynchronization therapy were associated with the greatest 24-month survival beneﬁt (adjusted odds ratio
for death 0.42, 95% conﬁdence interval (CI), 0.34–0.52; and 0.44, 95% CI, 0.29–0.67, respectively). Angiotensin-converting
enzyme inhibitors/angiotensin receptor blockers, implantable cardioverter-deﬁbrillators, anticoagulation for atrial ﬁbrillation, and
HF education were also associated with beneﬁt, whereas aldosterone antagonist use was not. Incremental beneﬁts were observed
with each successive therapy, plateauing once any 4 to 5 therapies were provided (adjusted odds ratio 0.31, 95% CI, 0.23–0.42 for
5 or more versus 0/1, P<0.0001).
Conclusions—Individual,withasingleexception,andincrementaluseofguideline-recommendedtherapieswasassociatedwithsur-
vival beneﬁt, with a potential plateau at 4 to 5 therapies. These data provide further rationale to implement guideline-recommended
HF therapies in the absence of contraindications to patients with HF and reduced left ventricular ejection fraction. (JA mH e a r t
Assoc 2012;1:16-26.)
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(HF) and reduced left ventricular ejection fraction (LVEF).1–4
Professional society guidelines for HF recommend the ap-
plication of these evidence-based therapies in eligible pa-
tients without contraindications.1–4 However, as a result of
the design most commonly used in randomized clinical trials,
where new therapies are tested on a background of existing
guideline-recommended therapies, the relative clinical value
of each new guideline-recommended therapy, independent of
other therapies, has not been well studied. Consequently, with
new evidence, professional society guidelines usually recom-
mend that each new therapy be added to other established
therapies.1–4 In addition, despite evidence from clinical trials,
questions remain about the translation of efﬁcacy and safety
ﬁndings from randomized clinical trials to real-world effective-
nessinclinicalpractice.5,6 Olderpatients,women,andpatients
in racial/ethnic minority groups are often underrepresented
in clinical trials.7–10 Observational clinical and comparative
effectiveness research thus has the potential to better inform
clinical decision making, especially where gaps exist in evi-
dence from clinical trials.11
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To date, a few observational study analyses have explored
the association of application of guideline-recommended ther-
apies with clinical outcomes in HF,12–15 but not the speciﬁc
and incremental contribution of each therapy. We sought to
explore the individual and incremental gains associated with
eachof7currentguideline-recommendedtherapiesforHFand
to evaluate their association with 24-month survival in outpa-
tients with chronic HF and reduced LVEF. To accomplish this,
we conducted a nested case-control study of patients with HF
drawn from the Registry to Improve the Use of Evidence-Based
Heart Failure Therapies in the Outpatient Setting (IMPROVE
HF) cohort.
Methods
Study Population
Thestudypopulationwasdrawnfromthelongitudinalcohortof
theIMPROVEHFregistry.IMPROVEHFwasaprospectivestudy
designed to evaluate the effectiveness of a practice-speciﬁc
performance improvement intervention on the use of selected
guideline-recommended therapies for outpatients with diag-
nosed HF and reduced LVEF or prior myocardial infarction
and LVEF. The overall study objectives and methods were
reported previously in detail.16,17 Community and academic
single- and multispecialty cardiology outpatient practices from
across the United States were invited to participate. Patients
with a clinical diagnosis of HF or prior myocardial infarction
documented on at least 2 separate visits were eligible for en-
rollment. Reduced LVEF was required to be demonstrated by a
quantitative LVEF ≤35% or by qualitative ﬁndings of moderate
to severe left ventricular systolic dysfunction on the most re-
cent echocardiogram, nuclear multiple gated acquisition scan,
contrastventriculogram,ormagneticresonanceimagingscan.
Patients with a noncardiovascular medical condition with an
estimated survival of <1 year and those who had undergone
cardiac transplantation were excluded.
Data Collection
Data were collected by medical chart review.16,17 Use of
selected guideline-recommended therapies was assessed at
baseline at all participating practices. After baseline data col-
lection, a practice-speciﬁc performance improvement inter-
vention was implemented, and use of recommended therapies
was reassessed at 12 and 24 months at all practices. Patient
demographic and clinical characteristics were also collected,
as were medical history, previous treatments, New York Heart
Association(NYHA)functionalstatus,QRSduration,laboratory
and diagnostic tests and results, treatments, and provision of
HF education. Contraindications and other reasons for not
administering the recommended therapies (eg, patient non-
compliance, patient refusal, and medical, economic, social,
and religious reasons) were collected from the chart when
documented. Collected practice characteristics included ge-
ographic region, outpatient practice setting (ie, university or
teaching versus nonuniversity or nonteaching), practice type
(single versus multispecialty), presence of a HF clinic in the
practice, stafﬁng (ie, number of physicians, HF nurses, electro-
physiologists, and interventionalists in the practice), number
of patients managed annually, type of medical record system
(electronic, paper, or mixed), and use of IMPROVE HF perfor-
mance improvement tools.
For each practice, medical records from patients with a
clinical diagnosis of HF or prior myocardial infarction and LVEF
≤35% were screened, and a representative sample of 90 pa-
tients per practice (on average) was randomly selected for
each follow-up assessment.16,17 The study was designed with
several measures to ensure data quality and accuracy. These
measures included the use of 34 trained, centralized chart
reviewers, who received ongoing training and testing by mem-
bers of the IMPROVE HF Steering Committee to ensure the
accuracy of data abstraction.16 Average interrater reliability
(κ statistic) was 0.82.17 Data quality reports were generated
monthly, and an average of 1.7 automated data quality checks
were performed on each data ﬁeld to ensure the values met
prespeciﬁed ranges, formats, and units. An audit of all patient
data as compared with source documentation was conducted
for 20% of the entire patient sample, using records from a 10%
random sample of practices. The mean data concordance rate
was 94.5% (range, 92.3% to 96.3%).17 Practices were required
to obtain institutional review board approval or waivers to par-
ticipateinIMPROVEHF.16 Theregistrycoordinatingcenterwas
Outcome Sciences, Inc (Cambridge, MA).
Deﬁnition of Cases and Controls
A nested matched case-control design was used because a
large cohort of patients was available in the IMPROVE-HF reg-
istry, enabling more explicit control of known powerful con-
founders, and because such an analysis would be less im-
pacted by loss to follow-up. Cases were deﬁned as patients
with HF who died from any cause within 24 months of follow-
up. All-cause mortality was used because it is less subject
to interpretation and was collected in IMPROVE HF. Cohort
patients who survived to 24 months were considered eligible
controls.
Matching
Casesandcontrolswerematchedonthebasisoftheirpropen-
sity score and matched at a 1:2 ratio using the greedy match-
ing technique.18 The propensity score in this analysis was the
probability of death. A logistic regression model was used to
generate the probability of death with dead/live as the out-
come and the following baseline characteristics as covariates:
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Patient characteristics in the model were age, race, insurance
status,HFetiology,atrialﬁbrillation,diabetes,chronicobstruc-
tive pulmonary disease, coronary artery bypass graft, periph-
eral vascular disease, depression, New York Heart Association
functional status, rales, edema, LVEF, systolic blood pressure,
diastolic blood pressure, heart rate, sodium, blood urea nitro-
gen,creatinine,potassium,andQRSduration;practicecharac-
teristics in the model were number of electrophysiologists in
practice, number of cardiologists in practice, type of medical
record system, and outpatient practice setting. No imputation
was done for any of the missing values, so the match was
generated on the basis of the nonmissing covariates. Vari-
ables with a large proportion of missing values, such as type B
natriuretic peptide and ethnicity, were not used for the match.
Guideline-Recommended Therapies
Seven guideline-recommended therapies were selected dur-
ing trial design by the IMPROVE HF Steering Committee16:u s e
of (1) angiotensin-converting enzyme inhibitor or angiotensin
receptor blocker (ACEI/ARB), (2) β-blocker, (3) aldosterone
antagonist, (4) anticoagulation for atrial ﬁbrillation/ﬂutter, (5)
cardiac resynchronization therapy (CRT) with a pacemaker or
deﬁbrillator, (6) implantable cardioverter-deﬁbrillator (ICD or
CRT with deﬁbrillator), and (7) patient education about HF.
Each therapy was selected on the basis of its potential to
improve patient outcomes, precision of deﬁnition, construct
and content validity, and feasibility.16 Patients who met the
guideline-speciﬁed eligibility criteria for each individual ther-
apy, with no contraindications, intolerance, or other docu-
mented reasons for not receiving it, were eligible for inclusion
in the analyses for that measure.16,17 Use of the HF education
measure was based on documentation in the medical record
thatthepatienthadreceivedwrittenorverbaleducationabout
HF. Documentation of New York Heart Association functional
class at a level consistent with guideline speciﬁcations is re-
quired to be eligible for aldosterone antagonist, CRT, or ICD
therapy; thus, only patients with quantitative or qualitative
evidence of New York Heart Association functional class doc-
umented in the medical record were included in analyses for
those measures.
Statistical Analysis
The IMPROVE HF longitudinal cohort consisted of 15 177 pa-
tients evaluated at the baseline, 12-month, and 24-month as-
sessments. For this study, the data collection forms were re-
quiredtohavecompletebaselinedataandvitalstatusrecorded
at 24 months. Descriptive summary statistics of baseline pa-
tient and practice characteristics were calculated for the case
and control groups and both groups combined. Continuous
variables were analyzed using the 2-sample t test, and cate-
gorical variables were analyzed with the chi-square test. The
baselinetreatmentrateforeachofthe7qualitymeasuresalso
wascalculatedforthecaseandcontrolgroups,anddifferences
between groups were compared using the chi-square test.
The primary analysis was designed to evaluate the associ-
ation between baseline use of the 7 guideline-recommended
HF therapies and mortality within 24 months of follow-up. For
each HF therapy, for eligible patients, the unadjusted odds ra-
tio (OR) of death was determined using a logistic regression
model with the therapy as the predictor variable and no covari-
ate adjustment. A univariate logistic regression analysis was
then performed for each patient and practice characteristic
assessed in this study to identify potential covariates for the
multivariate logistic model. All characteristics with a P value
≤0.10 in the univariate regression were considered potential
confounders. These characteristics were ﬁtted into a multi-
variate logistic regression model, with treatment as the main
effect and the potential confounders as covariates, to deter-
minetheORofdeathforeachguideline-recommendedtherapy
among therapy-eligible patients who received the treatment at
baseline versus therapy-eligible patients who did not receive
baseline treatment in each study group. Therapies were se-
quenced on the basis of their β-coefﬁcients and the order in
which they are commonly prescribed in clinical practice. Pa-
tientswhowerenottreatedatbaselinebutwhocrossedoverto
treatmentbymonth12ofthestudywereconsideredastreated
at baseline. Sensitivity analyses with these early crossover pa-
tients considered as untreated were also performed.
Anadditionalsetofanalyseswasconductedtoevaluatethe
association between total number of guideline-recommended
therapies received by all patients at baseline and death within
24 months. A logistic regression analysis using dead versus
alive as the outcome, number of therapies as the main effect,
and adjusting for other covariates, was conducted to calculate
ORs and 95% conﬁdence intervals (CIs) for each comparison
group. Patients who received 0 or 1 guideline-recommended
therapy were grouped together, as were those who received
5, 6, or 7 therapies, because of the low number of patients
receiving 0, 6, or 7 therapies. Reference value 0/1 was used
and was compared with 2, 3, 4, and 5/6/7 therapies. To
assess the cumulative contribution of applying each guideline-
recommended therapy, we used a logistic regression model
to calculate the OR of death at 24 months for each therapy
among the entire case-control population irrespective of eligi-
bility. The estimated cumulative contribution of applying each
of the guideline-recommended therapies sequentially was cal-
culated by adding the β-coefﬁcients for each therapy in order
of greatest to least impact, as presented by the OR of death
for multiple treatments versus no treatment. We also per-
formed an analysis of the sequential contribution of ACEI/ARB
followed by β-blockers, followed by CRT plus ICD, conﬁned
to the subgroup of patients eligible for each of these 4
key guideline-directed HF therapies. P<0.05 was considered
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statistically signiﬁcant for all analyses unless otherwise noted.
AnalyseswerecompletedwithSASstatisticalsoftware,version
9.1 (SAS Institute, Cary, NC).
Allauthorshadfullaccesstothedataandtakeresponsibility
foritsintegrity.Allauthorsapprovedthemanuscriptaswritten.
Results
Of the 15 177 patients in the IMPROVE HF longitudinal co-
hort,4128(27.2%)wereselectedthroughthepropensityscore
matching process. Of these, 1376 had a vital status of dead
at 24 months (cases), and 2752 were alive at 24 months (con-
trols). Overall, patient characteristics were very well matched
between groups (Table 1 ). Mean (standard deviation) age was
72.0 years (12.4 years) and 71.6 years (11.5 years) in cases
and controls, respectively (P=0.2396), and 71.2% and 72.2%,
respectively, were male (P=0.5246). Race was the only sta-
tistically signiﬁcantly different characteristic between cases
and controls (P=0.0006). Baseline practice characteristics,
calculated at the patient level, were also very well matched
between the case and control groups (Table 2). The majority
of practices in both groups were not afﬁliated with a university
or teaching facility (68.5% and 68.2% for cases and controls,
respectively), and the median number of patients managed an-
nually was 2319. Practices were also well matched in terms
of the number of cardiologists, electrophysiologists, interven-
tionalists, and HF nurses on staff.
Figure 1 shows the proportion of patients in the case and
control groups who received therapies for which they were el-
igible at baseline. Baseline treatment rates were signiﬁcantly
higher among controls who were eligible for an ACEI/ARB, β-
blocker, anticoagulation for atrial ﬁbrillation, ICD, CRT, and HF
education than among eligible cases. There was no difference
between the groups for patients eligible for aldosterone an-
tagonists. The baseline treatment rates among patients in this
nested analysis were similar to the rates observed in the over-
all IMPROVE HF patient population at baseline.17 The number
andproportionofcasesandcontrolsnewlyinitiatedontherapy
within 12 months are shown in Table 3.
Table 4 shows the unadjusted and adjusted ORs for 24-
month mortality among patients eligible for each therapy at
baseline.Afteradjustmentforpatientandpracticecharacteris-
tics, all guideline-recommended therapies except aldosterone
antagonists were shown to be independently associated with
a lower odds of death at 24 months. Use of β-blockers and
CRT were associated with the greatest reductions in the odds
of death (β-blocker 58% lower adjusted odds, adjusted OR
0.42, 95% CI, 0.34–0.52, P<0.0001 and CRT 56% lower ad-
justedodds,adjustedOR0.44,95%CI,0.29–0.67,P=0.0001).
ACEI/ARB, ICD, HF education, and anticoagulation for atrial
ﬁbrillation were also independently associated with lower ad-
justed odds of death. There was no signiﬁcant difference in
theadjusted odds of death associatedwithuse compared with
nonuse of aldosterone antagonists. In the sensitivity analyses,
use of β-blockers, ACEI/ARB, CRT, and ICD was also associ-
ated withstatisticallysigniﬁcantlyreduced odds of death at24
months.
Incremental beneﬁts for the guideline-recommended ther-
apies were observed. Patients who received a greater num-
ber of treatments at baseline were more likely to be alive at
24 months (Figure 2). The beneﬁt tended to plateau after 4
to 5 therapies. Sequential application of speciﬁc therapies,
in order of greatest to least individual associated beneﬁt (β-
Blocker, ACEI/ARB, ICD, HF education, and anticoagulation
for atrial ﬁbrillation), yielded the lowest odds of death at 24
months (Table 5 and Figure 3). Treatment with these 5 thera-
pies, as compared with no treatment, was independently as-
sociated with an 83% reduction in the odds of death within
24 months (adjusted OR 0.17, 95% CI, 0.12–0.23, P<0.0001).
When we separately analyzed whether ACEI/ARB, β-blockers,
CRT, and ICD would provide incremental beneﬁt with each
successive therapy if added to the model in the order in which
they are generally applied in clinical practice, including only
those patients eligible for all 4 therapies (N=368), succes-
sive beneﬁt was found for ACEI/ARB, ACEI/ARB+β-blocker,
andACEI/ARB+β-blocker+CRT+ICDcomparedwithnotreat-
ment (all 4 treatments compared with 0 treatments, adjusted
OR 0.10, 95% CI, 0.04–0.30, P<0.0001; Figure 4).
Discussion
This study is among the ﬁrst to examine the individual and
incremental clinical effectiveness of guideline-recommended
therapies for patients with HF and reduced LVEF. Analysis
of IMPROVE HF data using a nested case-control approach
revealed that with one exception, each of these guideline-
recommended therapies was associated with a decreased risk
of 24-month mortality. β-Blocker and CRT therapy had the
strongest 24-month survival beneﬁts observed. In addition,
there was incremental beneﬁt with each successive guideline-
recommended therapy. This strong positive association be-
tween progressive use of guideline-recommended therapies
and improved risk-adjusted survival did appear to plateau af-
ter any 4 to 5 therapies were applied. These ﬁndings pro-
vide further evidence supporting the clinical effectiveness of
guideline-recommendedHFtherapiesforpatientsencountered
in real-world clinical practice and suggest that there may be
incremental beneﬁts to the application of these therapies in
the outpatient practice setting. These data may also provide
furtherrationaleforusingsystems,performanceimprovement,
and disease management programs to ensure the implemen-
tation of guideline-recommended HF therapies into clinical
practice.
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Table 1. Baseline Patient Characteristics for the 1:2 Matched Cohort
Cohort
Characteristic Total (N=4128) Case (Dead) (N=1376) Control (Alive) (N=2752) P
Age, mean (SD), y 71.7 (11.8) 72.0 (12.4) 71.6 (11.5) 0.2396
Sex, n (%) 0.5246
Male 2966 (71.9%) 980 (71.2%) 1986 (72.2%)
Female 1162 (28.1%) 396 (28.8%) 766 (27.8%)
Race, n (%) 0.0006
Black 377 (9.1%) 145 (10.5%) 232 (8.4%)
White 1869 (45.3%) 627 (45.6%) 1242 (45.1%)
Other 69 (1.7%) 14 (1.0%) 55 (2.0%)
Not documented/missing 1813 (43.9%) 590 (42.9%) 1223 (44.4%)
Insurance, n (%) 0.4963
Medicare 2829 (68.5%) 953 (69.3%) 1876 (68.2%)
Medicaid 134 (3.2%) 52 (3.8%) 82 (3.0%)
Private 786 (19.0%) 242 (17.6%) 544 (19.8%)
Other 118 (2.9%) 43 (3.1%) 75 (2.7%)
None 37 (0.9%) 12 (0.9%) 25 (0.9%)
Not documented/missing 224 (5.4%) 74 (5.4%) 150 (5.5%)
Ischemic HF etiology, n (%) 2893 (70.1%) 996 (72.6%) 1897 (69.3%) 0.0781
History of atrial ﬁbrillation 1474 (35.7%) 492 (35.8%) 982 (35.7%) 0.9634
History of diabetes 1464 (35.5%) 495 (36%) 969 (35.2%) 0.6290
History of hypertension 2612 (63.3%) 874 (63.5%) 1738 (63.2%) 0.8194
Previous MI 1715 (41.5%) 557 (40.5%) 1158 (42.1%) 0.3258
History of COPD 801 (19.4%) 285 (20.7%) 516 (18.8%) 0.1329
History of coronary artery bypass grafting 1413 (34.2%) 476 (34.6%) 937 (34.0%) 0.7279
History of PCI 1082 (26.2%) 361 (26.2%) 721 (26.2%) 0.9800
History of PVD 514 (12.5%) 176 (12.8%) 338 (12.3%) 0.6407
History of depression 410 (9.9%) 151 (11.0%) 259 (9.4%) 0.1136
NYHA class, n (%) 0.2379
I 1335 (32.3%) 419 (30.5%) 916 (33.3%)
II 1612 (39.1%) 558 (40.6%) 1054 (38.3%)
III 990 (24%) 331 (24.1%) 659 (23.9%)
IV 84 (2%) 34 (2.5%) 50 (1.8%)
Not documented 107 (2.6%) 34 (2.5%) 73 (2.7%)
LVEF, % 0.3102
Mean (SD) 25.1 (7) 24.9 (7) 25.2 (7)
Median (25th, 75th percentiles) 25 (20, 30) 25 (20, 30) 25 (20, 30)
Systolic blood pressure, mm Hg, median (25th, 75th percentiles) 118 (106, 130) 118 (106, 130) 118 (108, 130) 0.7506
Diastolic blood pressure, mm Hg, median (25th, 75th percentiles) 70 (60, 76) 69 (60, 76) 70 (60, 76) 0.0785
Resting heart rate, beats/min, median (25th, 75th percentiles) 72 (64, 80) 72 (64, 80) 71.5 (64, 79) 0.7007
Pulmonary rales on last examination, n (%) 144 (3.5%) 41 (3.0%) 103 (3.7%) 0.4515
Edema on last examination, n (%) 896 (21.7%) 313 (22.7%) 583 (21.2%) 0.5173
Continued
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Table 1. Continued
Cohort
Characteristic Total (N=4128) Case (Dead) (N=1376) Control (Alive) (N=2752) P
Sodium, mEq/L, median (25th, 75th percentiles) 140 (137, 142) 139 (137, 142) 140 (137, 142) 0.5941
Serum urea nitrogen, mg/dL, median (25th, 75th percentiles) 23 (17, 31) 23 (17, 32) 23 (17, 30.5) 0.3465
Creatinine, mg/dL, median (25th, 75th percentiles) 1.3 (1, 1.6) 1.3 (1, 1.6) 1.3 (1, 1.6) 0.1723
Potassium, mEq/L, median (25th, 75th percentiles) 4.4 (4.1, 4.7) 4.4 (4.1, 4.8) 4.4 (4.1, 4.7) 0.8566
QRS duration, ms, median (25th, 75th percentiles) 130 (102, 160) 126 (104, 158) 132 (102, 160) 0.7010
COPD indicates chronic obstructive pulmonary disease; HF, heart failure; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; PCI,
percutaneous coronary intervention; PVD, peripheral vascular disease; and SD, standard deviation.
The beneﬁts associated with pharmacological and device
therapies observed in this study are consistent with key clin-
ical trials in HF. The ﬁndings of strong associations between
β-blocker and ACEI/ARB use and improved survival are con-
sistent with the wealth of clinical trial data demonstrating the
efﬁcacy of these therapies and with prior studies of clinical
effectiveness of these agents.14,19–21 A study of Medicare pa-
tients with HF and left ventricular systolic dysfunction showed
that a discharge prescription for either an ACEI or ARB was
associated with a 17% relative reduction in 1-year postdis-
charge mortality after risk adjustment.21 A clinical effective-
nessstudy ofβ-blocker therapyamongMedicarebeneﬁciaries
hospitalized with HF found that the use of β-blocker therapy
was independently associated with improved survival.14 The
current IMPROVE HF study provides further evidence support-
ing the clinical effectiveness of ACEI/ARB and β-blocker use
and extends these ﬁndings to a cohort not entirely limited to
Medicare patients. In the present analysis, anticoagulation for
atrial ﬁbrillation was also associated with a reduced risk of
mortality. This ﬁnding is consistent with clinical trials demon-
strating that anticoagulation for atrial ﬁbrillation reduces the
risk of fatal and nonfatal stroke in patients with HF.22 The clin-
ical effectiveness of CRT and ICD therapy is also supported
by this study. Use of CRT and ICD therapies has been shown
to reduce mortality in randomized clinical trials.15,23 In our
study, CRT was strongly and independently associated with
improved patient survival at 24 months. CRT has previously
been shown to be clinically effective in patients with HF.23 In
the present study, after adjustment for covariates, ICD use
was signiﬁcantly associated with a 38% lower odds of 2-year
mortality.PriorstudieshavealsoshownthatICDuseineligible
patients at the time of hospital discharge is associated with
reduced mortality over 1- and 3-year periods.14,15 In contrast,
aldosteroneantagonistusewasnotassociatedwithlowermor-
tality after multivariable adjustment. These ﬁndings are in con-
trast to randomized clinical trials demonstrating efﬁcacy1 and
prior studies of aldosterone antagonist use being associated
with lower mortality risk.14 These ﬁndings may have resulted
from confounding by indication or other forms of observa-
tional bias. Alternatively, aldosterone antagonist use may be
less effective or less safe as dosed and monitored in clinical
practice.9 Furtherstudiesof theclinicaleffectivenessof aldos-
teroneantagonistsinHFindiverseclinicalpracticesettingsare
needed.
As previously noted, by the very nature of placebo-
controlled randomized clinical trial design, new evidence sup-
porting new therapies provides evidence that is considered
additive.24 Hence, these studies inform clinicians about the
treatments that should be prescribed but rarely provide infor-
mation about which therapies may be omitted. Studies weigh-
ing the incremental value of well-established therapies in the
modern era of HF treatment have not been performed.24 Thus,
the evidence of incremental beneﬁt provided by guideline-
recommended HF therapies evaluated in the outpatient set-
ting for patients with chronic HF is valuable. Using a nested
case-control design, we were able to weigh the impact of sev-
eralguideline-recommendedHFtherapiesasappliedincurrent
clinical practice in real-world patients. With this analysis, esti-
matesof thesurvivaladvantage associatedwithsomeof these
therapies are in some cases greater than those observed in
clinical trials. This may be because patients enrolled in ran-
domized trials may not be fully representative of HF patients in
clinical practice. It is possible that this latter group may derive
even greater beneﬁt from the use of guideline-recommended
therapies. Nevertheless, selection bias and residual confound-
ing may also account for these ﬁndings.
With the expanding evidence base provided by clinical tri-
als, the number of evidence-based, guideline-recommended
HF therapies has increased. This increase has been consid-
ered by some to place additional burdens on patients and
physicians in terms of adherence and on health systems in
terms of resource allocation. By weighing the beneﬁts of
each guideline-recommend therapy with respect to 24-month
survival, this analysis may inform the choice between
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Table 2. Baseline Practice Characteristics: Patient-Level Analysis
Cohort
Characteristic Total (N=4128) Case (Dead) (N=1376) Control (Alive) (N=2752) P
Census region, n (%) 0.6075
South 1613 (39.1%) 553 (40.2%) 1060 (38.5%)
West 584 (14.1%) 185 (13.4%) 399 (14.5%)
Central 800 (19.4%) 258 (18.8%) 542 (19.7%)
Northeast 1131 (27.4%) 380 (27.6%) 751 (27.3%)
Outpatient practice setting, n (%) 0.2360
Nonuniversity, nonteaching 2821 (68.3%) 943 (68.5%) 1878 (68.2%)
Nonuniversity, teaching 914 (22.1%) 316 (23%) 598 (21.7%)
University, teaching 393 (9.5%) 117 (8.5%) 276 (10%)
Multispecialty, n (%) 943 (22.8%) 325 (23.6%) 618 (22.5%) 0.4015
Electronic health record system, n (%) 0.3758
Paper 1933 (46.8%) 636 (46.2%) 1297 (47.1%)
Electronic 1443 (35.0%) 473 (34.4%) 970 (35.2%)
Mixed 752 (18.2%) 267 (19.4%) 485 (17.6%)
HF nurse in practice (>1F T EA P N ) ,n (%) 1698 (41.1%) 553 (40.2%) 1145 (41.6%) 0.3628
No. of electrophysiologists in practice 0.4108
Mean (SD) 1.7 (1.7) 1.7 (1.7) 1.7 (1.8)
Median (25th, 75th percentiles) 1 (0, 3) 1 (0, 3) 1 (0, 3)
No. of interventionalists in practice 0.6872
Mean (SD) 5.1 (3.3) 5 (3.3) 5.1 (3.3)
Median (25th, 75th percentiles) 5 (3, 6) 5 (3, 6) 5 (3, 6)
No. of HF clinic sessions in practice 0.9649
Mean (SD) 1.5 (0.5) 1.5 (0.5) 1.5 (0.5)
Median (25th, 75th percentiles) 2 (1, 2) 2 (1, 2) 2 (1, 2)
No. of cardiologists in practice 0.2364
Mean (SD) 13.9 (11.6) 13.6 (10.9) 14 (11.9)
Median (25th, 75th percentiles) 10 (7, 18) 10 (7, 18.5) 10 (7, 18)
No. of HF patients managed annually 0.6948
Mean (SD) 3601 (3968.6) 3565 (3820.2) 3619.4 (4043)
Median (25th, 75th percentiles) 2319 (700, 5000) 2319 (750, 5000) 2319 (700, 5000)
APN indicates advanced practice nurse; FTE, full-time equivalent; HF, heart failure; SD, standard deviation.
therapiesandstrategieswhensuchdecisionsneedtobemade.
In addition, this analysis explored the relative mortality reduc-
tionassociatedwitheachguideline-recommendedtherapyand
describes the proportion of lives that may be preserved with
more complete application of each of the HF therapies. At
a clinical level, being able to independently value these HF
therapies may provide the rationale for choosing among treat-
ments when a choice must be made, whether for reasons of
cost, tolerance, or adherence. Among the HF therapies evalu-
ated in this analysis, β-blocker and CRT seemed to impart the
greatest individual beneﬁts. These therapies may be among
the priorities for focused efforts to improve implementation
of HF quality improvement programs such as Get With The
Guidelines-HF. The ﬁnding of a potential plateau in survival
beneﬁt after any 4 to 5 guideline-recommended HF therapies
were applied, if conﬁrmed in additional studies, may also help
to better inform clinical decision making and the design of HF
quality improvement efforts.
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Figure 1. Use of guideline-recommended therapies at baseline
in cases and controls. Baseline use of each of the guideline-
recommended therapies for cases (dead at 24 mo) compared with
controls (alive at 24 mo). ACEI indicates angiotensin-converting
enzyme inhibitor; AF, atrial ﬁbrillation; ARB, angiotensin receptor
blocker; CRT, cardiac resynchronization therapy (with deﬁbrillator
or pacemaker); HF, heart failure; ICD, implantable cardioverter-
deﬁbrillator (including CRT with deﬁbrillator).
Limitations
Certain limitations inherent in the design of IMPROVE HF and
this analysis should be considered. Medical chart review with
data abstraction was the source of patient clinical data. Every
effort was made to ensure the accuracy and completeness
of these data through consistent regular training of personnel
involved in the medical chart review process, but it is possi-
ble that errors and omissions could have occurred. It is also
possible that some proportion of patients considered eligible
for treatment who were not treated at each time point may
have had contraindications or other reasons that prevented
treatment but were not documented in the medical record. In
addition, this analysis was conﬁned to patients with complete
follow-up at 24 months, and in the primary analyses patients
withearlycrossovertotreatmentwereconsideredastreatedat
baseline, which may have introduced bias. As with all observa-
tional studies, the possibility for unmeasured bias exists, thus,
leading to overestimation or underestimation of treatment ef-
fects.Wecouldnotadjustforsocioeconomicfactorsorpatient
adherence.Withthecase-controldesign,theindividualtherapy
analyses did not adjust for use of other background therapies.
Therearedifferentialindicationsforeachtherapyasafunction
of HF severity, which, even after propensity matching and risk
adjustment, may still have inﬂuenced the incremental beneﬁt
analyses. There may also be other measured or unmeasured
confounding variables that would have strengthened or weak-
ened the association for some or all of the therapies. The ma-
jorityofpatientswhoreceivedCRTreceivedaCRT-deﬁbrillator
device. This high concordance for these two therapies likely
diminished the ability to ascertain the incremental beneﬁt of
CRT in some of the analyses. The associations between use
Table 3. Proportion of Treated Patients Who Received
Treatment at Baseline and Proportion Who Crossed Over to
Treatment by 12 Months∗
Therapy
Treatment at
Baseline
No Treatment at
Baseline, Crossed
Over to Treatment
by 12 Months
ACEI/ARB
Cases (dead) 936 (96.6%) 33 (3.4%)
Controls (alive) 2062 (92.8%) 159 (7.2%)
β-Blocker
Cases (dead) 1018 (96.1%) 41 (3.9%)
Controls (alive) 2206 (94.6%) 126 (5.4%)
Aldosterone antagonists
Cases (dead) 118 (92.9%) 9 (7.1%)
Controls (alive) 203 (82.5%) 43 (17.5%)
Anticoagulation for atrial ﬁbrillation
Cases (dead) 292 (95.1%) 15 (4.9%)
Controls (alive) 652 (94.4%) 39 (5.6%)
ICD
Cases (dead) 453 (88.3%) 60 (11.7%)
Controls (alive) 1016 (81.9%) 224 (18.1%)
CRT
Cases (dead) 49 (72.1%) 19 (27.9%)
Controls (alive) 121 (67.2%) 59 (32.8%)
HF education
Cases (dead) 874 (83.9%) 168 (16.1%)
Controls (alive) 1688 (75.2%) 558 (24.8%)
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; CRT, cardiac resynchronization therapy; HF, heart failure; ICD, implantable
cardioverter-deﬁbrillator.
∗This table shows the proportion of those patients treated at baseline of the total
patients treated and the proportion of patients with early crossover of the total patients
treated.
of guideline-recommended therapies and mortality do not de-
termine causality. Although these associations may reﬂect the
clinical effectiveness of these treatments, they may alterna-
tively reﬂect treatment selection bias, which would tend to
favor these associations. The ORs may have been magniﬁed
by confounding. Although the baseline treatment rates in IM-
PROVEHFweresimilartothoseof otherstudiesofHF patients
incardiologypractices,25 theseﬁndingsmaynotapplytoprac-
tices that differ from the IMPROVE HF outpatient cardiology
practices.
Conclusions
This analysisofIMPROVEHFdatademonstratesthatguideline-
recommended therapies for patients with HF and reduced
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Table 4. Association Between Treatment With Guideline-Recommended Therapy at Baseline and Mortality Within 24 Months of
Follow-Up: Univariate and Multivariate Logistic Regression Models*
Therapy Treated n (%) Not Treated n (%) Unadjusted OR (95% CI) P Adjusted OR (95% CI) P
ACEI/ARB
Cases (dead) 969 (77.9%) 275 (22.1%) 0.56 (0.47–0.66) <0.0001 0.56 (0.47–0.67) <0.0001
Controls (alive) 2221 (86.4%) 351 (13.6%)
β-Blocker
Cases (dead) 1059 (84.1%) 200 (15.9%) 0.42 (0.34–0.52) <0.0001 0.42 (0.34–0.52) <0.0001
Controls (alive) 2332 (92.6%) 185 (7.4%)
Aldosterone antagonists
Cases (dead) 127 (43.9%) 162 (56.1%) 1.13 (0.85–1.50) 0.4047 1.05 (0.74–1.51) 0.7707
Controls (alive) 246 (41.0%) 354 (59.0%)
Anticoagulation for atrial ﬁbrillation
Cases (dead) 307 (69.1%) 137 (30.9%) 0.72 (0.56–0.92) 0.0096 0.73 (0.57–0.95) 0.0179
Controls (alive) 691 (75.8%) 221 (24.2%)
ICD
Cases (dead) 513 (52.0%) 473 (48.0%) 0.62 (0.53–0.72) <0.0001 0.62 (0.53–0.73) <0.0001
Controls (alive) 1240 (63.6%) 709 (36.4%)
CRT
Cases (dead) 68 (41.2%) 97 (58.8%) 0.55 (0.38–0.80) 0.0020 0.44 (0.29–0.67) 0.0001
Controls (alive) 180 (56.1%) 141 (43.9%)
HF education
Cases (dead) 1042 (75.7%) 334 (24.3%) 0.70 (0.60–0.82) <0.0001 0.73 (0.62–0.85) <0.0001
Controls (alive) 2246 (81.6%) 506 (18.4%)
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; DBP,
diastolic blood pressure; EHR, electronic health record; HF, heart failure; ICD, implantable cardioverter-deﬁbrillator; LVEF, left ventricular ejection fraction; NYHA, New York Heart
Association; SBP, systolic blood pressure.
*The analysis for each individual therapy included only patients eligible for that therapy. Variables retained in the models were as follows: ACEI/ARB: race, depression, DBP; β-blocker:
race, HF etiology, DBP; aldosterone antagonist: age, sex, COPD, LVEF, SBP, DBP, QRS, HF clinic in practice, EHR group; anticoagulation for atrial ﬁbrillation: age, NYHA class, DBP,
multispecialty practice; ICD: EHR group; CRT: age, edema, LVEF, SBP, DBP, HF clinic in practice, EHR group, APN in practice, outpatient setting; and HF education: race, HF etiology, DBP.
LVEF are associated with decreased risk of 24-month mor-
tality. β-Blocker and CRT therapy had the strongest 24-month
survival beneﬁts observed. In addition, there was an incre-
mental beneﬁt with each successive guideline-recommended
therapy. This strong positive association between progressive
use of guideline-recommended therapies and improved risk-
adjusted survival plateaued after any 4 to 5 therapies were
applied.Theseﬁndingsprovidefurtherevidencefortheclinical
Table 5. Cumulative Effect of Sequential Application of Guideline-Recommended Heart Failure Therapies on 24-Month Mortality*
Therapy No. (%) of Patients Adjusted OR (95% CI) P P (incremental)
β-Blocker 3477 (84.2%) 0.61 (0.51–0.72) <0.0001 <0.0001
β-Blocker+ACEI/ARB 2461 (59.6%) 0.37 (0.29–0.46) <0.0001 <0.0001
β-Blocker+ACEI/ARB+ICD 1397 (33.8%) 0.24 (0.19–0.32) <0.0001 <0.0001
β-Blocker+ACEI/ARB+ICD+HF education 1169 (28.3%) 0.19 (0.14–0.25) <0.0001 0.0038
β-Blocker+ACEI/ARB+ICD+HF education+anticoagulation for AF 400 (9.7%) 0.17 (0.12–0.23) <0.0001 0.1388
β-Blocker+ACEI/ARB+ICD+HF education+anticoagulation for AF+CRT 81 (2.0%) 0.19 (0.13–0.28) <0.0001 0.1208
ACEI indicates angiotensin-converting enzyme inhibitor; AF, atrial ﬁbrillation; ARB, angiotensin receptor blocker; CI, conﬁdence interval; CRT, cardiac resynchronization therapy (with
deﬁbrillator or pacemaker); HF, heart failure; ICD, implantable cardioverter-deﬁbrillator (including CRT with deﬁbrillator); OR, odds ratio.
*Variables retained in the model were race, HF etiology, and diastolic blood pressure.
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Figure 2. ORs for 24-month mortality associated with the number
of guideline-recommended therapies received at baseline. Analysis
includes all patients from the case-control population (N=4128). The
number(%)ofpatientsreceivingeachnumberoftherapiesatbaseline
was as follows: 0 or 1, 238 (5.8%); 2, 712 (17.3%); 3, 1327 (32.2%);
4, 1123 (27.2%); and 5, 6, or 7, 728 (17.6%). OR indicates odds ratio.
Figure 3. Cumulative percent reduction in odds of death at 24
months with each sequentially applied guideline-recommended HF
therapy.Therapiesweresequencedonthebasisoftheirβ-coefﬁcients
and the order in which they are commonly applied clinically. Vari-
ables retained in the model were race, HF etiology, and dias-
tolic blood pressure. Incremental P values for the sequentially ap-
plied therapies (left to right) were as follows: <0.0001, <0.0001,
<0.0001, 0.0038, 0.1388, and 0.1208, respectively. ACEI indicates
angiotensin-converting enzyme inhibitor; AF, atrial ﬁbrillation; ARB,
angiotensin receptor blocker; CRT, cardiac resynchronization therapy
(with deﬁbrillator or pacemaker); HF, heart failure; ICD, implantable
cardioverter-deﬁbrillator (including CRT with deﬁbrillator).
effectiveness of guideline-recommended HF therapies among
patients encountered in real-world clinical practice. Further,
they suggest that beneﬁt accrues incrementally with applica-
tion of these therapies in the outpatient setting. These data
provide further rationale for using systems, performance im-
provement, and HF disease management programs to ensure
the implementation of guideline-recommended HF therapies
into clinical practice.
Figure 4. Cumulative percent reduction in odds of death at 24
months associated with sequential treatments compared with no
treatment. Analysis includes only patients eligible for all 4 therapies
(N=368). ACEI indicates angiotensin-converting enzyme inhibitor;
ARB, angiotensin receptor blocker; CRT, cardiac resynchronization
therapy; ICD, implantable cardioverter-deﬁbrillator.
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